You just read:

Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis

News provided by

AbbVie

Apr 09, 2018, 08:45 ET